GlassScriptPhysician profile
Adam Jonathan Kaplan
NPI 1245322056
$5,991.63
in general payments reported to CMS, 2019-2025
43 companies · $885 in 2025
The $885 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $1,074 · 2021: $1,205 · 2022: $659 · 2023: $511 · 2024: $855 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,250.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,678.04 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $478.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $422.61 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $383.46 | 2019-2024 | Trintellix |
| Abbvie INC. | $316.07 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $294.57 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $291.19 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.71 | 2019-2025 | Jardiance |
| Abbott Laboratories | $188.59 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Vivus LLC | $183.76 | 2019-2022 | |
| Pfizer INC. | $175.84 | 2019-2025 | |
| Currax Pharmaceuticals LLC | $169.62 | 2020-2025 | Contrave |
| Amgen INC. | $168.34 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $163.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Eisai INC. | $115.89 | 2020-2021 |
Show all 39 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.